Pimavanserin Tartrate Patent Expiration
Pimavanserin Tartrate is used for treating symptoms of neurodegenerative diseases such as Parkinson's psychosis and hallucinations. It was first introduced by Acadia Pharmaceuticals Inc
Pimavanserin Tartrate Patents
Given below is the list of patents protecting Pimavanserin Tartrate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Nuplazid | US10449185 | Formulations of pimavanserin | Aug 27, 2038 | Acadia Pharms Inc |
| Nuplazid | US10646480 | Formulations of pimavanserin | Aug 27, 2038 | Acadia Pharms Inc |
| Nuplazid | US10849891 | Formulations of pimavanserin | Aug 27, 2038 | Acadia Pharms Inc |
| Nuplazid | US11452721 | Formulations of pimavanserin | Aug 27, 2038 | Acadia Pharms Inc |
| Nuplazid | US10517860 | Combination of pimavanserin and cytochrome P450 modulators | Mar 23, 2037 | Acadia Pharms Inc |
| Nuplazid | US10953000 | Combination of pimavanserin and cytochrome P450 modulators | Mar 23, 2037 | Acadia Pharms Inc |
| Nuplazid | US7601740 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases | Apr 29, 2030 | Acadia Pharms Inc |
| Nuplazid | US7732615 | N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms | Jun 03, 2028 | Acadia Pharms Inc |
| Nuplazid | US7659285 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases | Aug 24, 2026 | Acadia Pharms Inc |
| Nuplazid | US7923564 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms | Sep 26, 2025 | Acadia Pharms Inc |
| Nuplazid | US10028944 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan 15, 2024
(Expired) | Acadia Pharms Inc |
| Nuplazid | US8618130 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan 15, 2024
(Expired) | Acadia Pharms Inc |
| Nuplazid | US8921393 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan 15, 2024
(Expired) | Acadia Pharms Inc |
| Nuplazid | US9566271 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan 15, 2024
(Expired) | Acadia Pharms Inc |
| Nuplazid | US9765053 | Methods of treatment using selective 5-HT2A inverse agonists |
Jul 27, 2022
(Expired) | Acadia Pharms Inc |
| Nuplazid | US7115634 | 4-aminopiperidine and their use as a medicine |
Oct 06, 2021
(Expired) | Acadia Pharms Inc |
| Nuplazid | US6756393 | Azacyclic compounds |
Mar 06, 2021
(Expired) | Acadia Pharms Inc |
| Nuplazid | US6815458 | Azacyclic compounds |
Mar 06, 2021
(Expired) | Acadia Pharms Inc |
| Nuplazid | US9296694 | Azacyclic compounds |
Mar 06, 2021
(Expired) | Acadia Pharms Inc |
| Nuplazid | US7858789 | Derivatives of 4-aminopiperidine and their use as a medicament |
Dec 13, 2020
(Expired) | Acadia Pharms Inc |
| Nuplazid | US8110574 | Derivatives of 4-aminopiperidine and their use as a medicament |
Dec 13, 2020
(Expired) | Acadia Pharms Inc |
Pimavanserin Tartrate's Family Patents
Explore Our Curated Drug Screens
Pimavanserin Tartrate Generic API Manufacturers
Several generic applications have been filed for Pimavanserin Tartrate. The first generic version for Pimavanserin Tartrate was by Zydus Worldwide Dmcc and was approved on Jan 16, 2024. And the latest generic version is by Msn Laboratories Private Ltd and was approved on Jan 16, 2024.
Given below is the list of companies who have filed for Pimavanserin Tartrate generic, along with the locations of their manufacturing plants worldwide.
1. MSN
Msn Laboratories Private Ltd has filed for 1 generic for Pimavanserin Tartrate. This eq 34mg base version comes by the name PIMAVANSERIN. Given below are the details of the strengths of this generic introduced by Msn.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 34MG BASE | capsule | Discontinued | ORAL | N/A | Jan 16, 2024 |
Manufacturing Plant Locations New
Msn's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Msn as present at those locations.
| Country | City | Firm Name | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||||||||
| United States |
| |||||||||||||||||||||
2. ZYDUS
Zydus Worldwide Dmcc has filed for 2 different strengths of generic version for Pimavanserin Tartrate. All of these versions come by the name PIMAVANSERIN. Given below are the details of the strengths of this generic introduced by Zydus.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 34MG BASE | capsule | Discontinued | ORAL | N/A | Jan 16, 2024 |
| EQ 10MG BASE | tablet | Discontinued | ORAL | N/A | Jan 16, 2024 |
Manufacturing Plant Locations New
Zydus's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Zydus as present at those locations.
| Country | City | Firm Name | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||||||||||
| United States |
| |||||||||||||||||||||||